Imaging biomarkers based on multiphase CT data in differentiation of renal cell carcinoma


  • Yu.O. Mytsyk Lviv national medical university n.a. Danylo Halytsky, Ukraine
  • Yu.B. Borys Lviv national medical university n.a. Danylo Halytsky, Ukraine
  • I.Yu. Dutka Medical center “Euroclinic”, Ukraine
  • I.V. Dats Lviv national medical university n.a. Danylo Halytsky, Ukraine
  • S.M. Pasichnyk Lviv national medical university n.a. Danylo Halytsky, Ukraine
  • D.Z. Vorobets Lviv national medical university n.a. Danylo Halytsky, Ukraine
  • A.R. Kucher Medical center “Ultramed”, Ukraine
  • B.Yu. Borys Lviv regional clinical hospital, Ukraine



renal-cell carcinoma, computed tomography, biomarker, diagnostics, radiodensity


Background. Renal-cell carcinoma (RCC) is one of 10 mostly widely spread malignant tumors in the world. Recently scientists focused on investigation of new imaging biomarkers of RCC based on USG, CT, MRI and radionuclide examinations data in order to increase efficiency of current pathology diagnostics. The goal of this study was to evaluate an efficiency of application of the novel biomarkers based on multiphase CT in differential diagnostics of RCC. Materials and methods. In total 120 patients with solid renal tumors >4 cm in greatest dimension in whom nephrectomy followed by pathological analysis were enrolled into this retrospective study: 84 (70,0%) with RCC, 14 (11,67%) with transitional cell carcinoma of renal pelvis and 22 (18,33%) with benign renal tumors. We analyzed and compared pathologic and multiphase CT data. Results. Using of signal intensity with threshold 54,80 HU allowed to differentiate RCC from other renal tumors with sensitivity and specificity accordingly 98,8% and 69,4% (AUC=0,844, 95% CI=0,746–0,942, р<0,001) on excretory CT images. Differentiation of RCC and benign renal tumors using signal intensity with threshold of 61,84 HU demonstrated 79,8% sensitivity and 63,6% specificity (AUC=0,745, 95% CІ=0,599–0,891, р<0,001) on excretory CT images. Differentiation of conventional RCC histologic subtype from non-conventional using signal intensity of nephrographic CT images with threshold 79,39 HU was possible with 71,7% specificity and 54,8% sensitivity (AUC=0,718, 95% CІ=0610–0,826, р=0,001). Identification of papillary and chromophobe subtypes as well as Fuhrman grades of clear-cell RCC was also possible. Conclusions. Application of radiodensity of tumor measured using multiphase CT as diagnostic imaging biomarker of solid RCC is valuable clinical tool for differentiation of current pathology, its histologic subtypes and Fuhrman grades. The drawback of the method is relatively high radiation exposure of the patient.


Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA., SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD, 2017.

Fujii Y., Saito K., Iimura Y. et al. Incidence of Benign Pathologic Lesions at Nephrectomy for Renal Masses Presumed to Be Stage I Renal Cell Carcinoma in Japanese Patients: Impact of Sex, Age, and Tumor Size. ASCO Meeting Abstracts. – 2011. – № 7(29). – Р. 374.

Link Richard E., Sam B. Bhayani, Mohammed E. Allaf, Ioannis Varkarakis, Takeshi Inagaki, Craig Rogers, Li-Ming Su, Thomas W. Jarrett, and Louis R. Kavoussi. “Exploring the Learning Curve, Pathological Outcomes and Perioperative Morbidity of Laparoscopic Partial Nephrectomy Performed for Renal Mass.” The Journal of Urology 173, no. 5 (May 2005): 1690–1694. doi:10.1097/01.ju.0000154777.24753.1b.

Wang, Hai-yi, Zi-hua Su, Xiao Xu, Ning Huang, Zhi-peng Sun, Ying-wei Wang, Lu Li, et al. “Dynamic Contrast-Enhanced MRI in Renal Tumors: Common Subtype Differentiation Using Pharmacokinetics.” Scientific Reports 7, no. 1 (June 8, 2017): 3117. doi:10.1038/s41598-017-03376-7.

Mains Jill Rachel, Frede Donskov, Erik Morre Pedersen, Hans Henrik Torp Madsen, and Finn Rasmussen. “Dynamic Contrast-Enhanced Computed Tomography as a Potential Biomarker in Patients with Metastatic Renal Cell Carcinoma: Preliminary Results from the Danish Renal Cancer Group Study-1.” Investigative Radiology 49, no. 9 (September 2014): 601–7. doi:10.1097/RLI.0000000000000058.

Nathan, Paul, Anup Vinayan. “Imaging Techniques as Predictive and Prognostic Biomarkers in Renal Cell Carcinoma.” Therapeutic Advances in Medical Oncology 5, no. 2 (March 2013): 119–131. doi:10.1177/1758834012463624.

Khandani, Amir H., and W. Kimryn Rathmell. “Positron Emission Tomography in Renal Cell Carcinoma: An Imaging Biomarker in Development.” Seminars in Nuclear Medicine 42, no. 4 (July 2012): 221–230. doi:10.1053/j.semnuclmed.2012.02.002.

Mytsyk Y, Dutka I, Yuriy B, Maksymovych I, Caprnda M, Gazdikova K, et al. Differential diagnosis of the small renal masses: role of the apparent diffusion coefficient of the diffusion-weighted MRI. Int Urol Nephrol. 2017 Dec 11;1–8.